Department of Translational Biomedicine and Neuroscience, University of Bari Medical School, Bari, Italy.
Department of Medicine and Surgery, Libera Università del Mediterraneo (LUM) Giuseppe Degennaro University, Bari, Italy.
Clin Exp Med. 2024 Jan 29;24(1):26. doi: 10.1007/s10238-023-01291-y.
A link exists between chronic inflammation and cancer and immune cells, angiogenesis, and tumor progression. In hematologic malignancies, tumor-associated macrophages (TAMs) are a significant part of the tumor microenvironment. Macrophages are classified into M1/classically activated and M2/alternatively activated. In tumors, TAMs are mainly constituted by M2 subtype, which promotes angiogenesis, lymphangiogenesis, repair, and remodeling, suppressing adaptive immunity, increasing tumor cell proliferation, drug resistance, histological malignancy, and poor clinical prognosis. The aim of our review article is to define the role of TAMs and their relationship with the angiogenesis in patients with lymphoma reporting both an analysis of main published data and those emerging from our studies. Finally, we have discussed the anti-angiogenic approach in the treatment of lymphomas.
慢性炎症与癌症之间存在关联，而免疫细胞、血管生成和肿瘤进展也与之相关。在血液恶性肿瘤中，肿瘤相关巨噬细胞（TAMs）是肿瘤微环境的重要组成部分。巨噬细胞分为 M1/经典激活型和 M2/替代激活型。在肿瘤中，TAMs 主要由 M2 亚型组成，它促进血管生成、淋巴管生成、修复和重塑，抑制适应性免疫，增加肿瘤细胞增殖、耐药性、组织学恶性程度和不良临床预后。我们这篇综述文章的目的是定义 TAMs 的作用及其与淋巴瘤患者血管生成的关系，报告主要已发表数据和我们研究中出现的新数据。最后，我们讨论了抗血管生成方法在淋巴瘤治疗中的应用。
